Sarcio, Inc.
Minnetonka, Minnesota, United States
Beth Lindborg is a Founder and the Chief Executive Officer of Sarcio Inc., a regenerative medicine company spun out from the University of Minnesota Stem Cell Institute. Under her leadership, Sarcio is developing a regenerative, disease modifying, exosome therapy for the treatment of Osteoarthritis, with the goal of delaying or eliminating the need for joint replacement surgery.
She holds an MS in Molecular, Cellular, and Developmental Biology and Genetics and an MBA from the University of Minnesota.
Lindborg brings deep experience in both startups and established life-science organizations. She previously served as Vice President of Strategy and Operations at SynerFuse, Inc., contributing to its angel funding success and FDA IDE approval, and held leadership roles in research and marketing at BRTI Life Sciences, spearheading product launches. She is deeply committed to translating regenerative science into meaningful therapies that improve the lives of patients.
1786: SEV-101, A Regenerative Exosome Therapeutic for the Treatment of Osteoarthritis
Tuesday, October 28, 2025
10:30 AM - 12:30 PM Central Time
Disclosure(s): No financial relationships with ineligible companies to disclose
